Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol

INTRODUCTION: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels <1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate (MTX). TEPs with hCG >1000 I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Horne, Andrew W, Skubisz, Monika M, Doust, Ann, Duncan, W Colin, Wallace, Euan, Critchley, Hilary O D, Johns, Terrance G, Norman, Jane E, Bhattacharya, Siladitya, Mollison, Jill, Rassmusen, Michael, Tong, Stephen
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2013
Matèries:
Obstetrics and Gynaecology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717468/
https://ncbi.nlm.nih.gov/pubmed/23872290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2013-002902
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars